Childhood cancers
Sub Category
Study Name
AAML1031: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD
Principal Investigator
Renuka Gera, MD
Study Information
Contact for Questions
Neelam Singh, PhD: 517-364-5591

Site view: at a glance